North America Epilepsy Drugs Market Forecast to 2030 - Regional Analysis

List of Tables

The North America epilepsy drugs market was valued at US$ 2,575.83 million in 2022 and is expected to reach US$ 3,609.34 million by 2030; it is estimated to grow at a CAGR of 4.3% from 2022 to 2030.

Growing Prevalence of Epilepsy Fuels the North America Epilepsy Drugs Market

Epilepsy is a neurological disorder characterized by recurrent seizures. According to the data published by the World Health Organization in February 2023, epilepsy accounts for a significant share of the global disease burden, affecting nearly 50 million people across the world. The projected proportion of the general population with active epilepsy (i.e., with the need for treatment or continuing seizures) at a given time is between 4 and 10 per 1,000 individuals.

According to the same source (World Health Organization in February 2023), 5 million people are diagnosed with epilepsy every year worldwide. High-income countries are estimated to report epilepsy at a rate of 49 per 100,000 people annually. In low- and middle-income countries, this number can be as high as 139 per 100,000 individuals. This is likely due to the high risk of endemic conditions such as neurocysticercosis or malaria, birth-related injuries, and a high incidence of road traffic injuries. About 80% of individuals with epilepsy live in low- and middle-income countries. The data also reports that seizures can be controlled, and about 70% of individuals living with epilepsy could become seizure-free with appropriate use of antiseizure medicines. Antiepileptic drug therapy is the primary treatment for most patients with epilepsy. Seizure classification is a crucial element in designing the treatment plan, as some antiepileptic drugs have different effects against various seizure types.

Thus, the rising prevalence and incidence of epilepsy worldwide are contributing to elevate the demand for epilepsy drugs.

North America Epilepsy Drugs Market Overview

The North America epilepsy drugs market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed due to the rise in number of people affected with epilepsy, growing aging population, ongoing R&D in the field of epilepsy drugs in the region, growing regulatory approvals for new product, and rise in number of accidents and brain injuries in epilepsy drugs.

North America Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

North America Epilepsy Drugs Market Segmentation

The North America epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the North America epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the North America epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the North America epilepsy drugs market is segmented the US, Canada, and Mexico. The US dominated the North America epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, Catalyst Pharmaceuticals Inc, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd, and UCB SA are some of the leading companies operating in the North America epilepsy drugs market.

Product Code: BMIRE00029804

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Epilepsy Drugs Market Landscape

4.1 Overview

5. North America Epilepsy Drugs Market - Key Industry Dynamics

5.1 Market Drivers
- 5.1.1 Growing Prevalence of Epilepsy
- 5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
- 5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
- 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
- 5.4.1 Increasing Product Approvals
5.5 Impact Analysis

6. Epilepsy Drugs Market - North America Market Analysis

6.1 Overview
6.2 North America Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030

7. North America Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

7.1 Overview
7.2 North America Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
- 7.3.1 Overview
- 7.3.2 First Generation Antiepileptics: North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
- 7.4.1 Overview
- 7.4.2 Second Generation Anti-epileptics: North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
- 7.5.1 Overview
- 7.5.2 Third Generation Anti-epileptics: North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 North America Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacy: North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
- 8.4.1 Overview
- 8.4.2 Retail Pharmacy Stores: North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis

9.1 North America Epilepsy Drugs Market

10. Epilepsy Drugs Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 UCB SA
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Novartis AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Pfizer Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 GSK Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Abbott Laboratories
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Sanofi SA
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms